Category

AIM Investors

Motif Bio Phase 3 clinical trial finishes patient treatment phase

By | AIM Investors
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI). REVIVE-1 is a 600-patient double-blinded, global, multicentre trial, in patients with ABSSSI that compares the safety and efficacy of an 80mg intravenous dose of iclaprim with 15mg/kg intravenous vancomycin. Treatments were administered every 12 hours for 5 to 14 days. Data read-out is expected in the second quarter of 2017. Data read-out for REVIVE-2 is anticipated in the second half of 2017. Successful completion of the two REVIVE trials is...
Read More

Issue of Equity and Total Voting Rights

By | AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 143,700 new ordinary shares in the Company ("Ordinary Shares") as a result of the exercise of options. Application has been made for the 143,700 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 13 January 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 195,885,228 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they...
Read More

Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights

By | AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces, that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company ("Ordinary Shares") following the conversion by Amphion Innovations plc and Amphion Innovations US Inc., (the “Amphion Parties”) of the Convertible Promissory Notes (“CPNs”). The CPNs which totalled US$3,550,786 were converted in accordance with their terms at US$0.2447 per share. Following the conversion, the Amphion Parties will hold no further CPNs and their holding will total 43,240,645 ordinary shares being 22 per cent. of the Company. Richard Morgan and Robert Bertoldi, Non-Executive Chairman and Executive Director of the Company respectively, are also directors of Amphion Innovations plc (the “Amphion Directors”). Amphion Innovations plc...
Read More

Issue of Equity and Total Voting Rights

By | AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 467,024 new ordinary shares in the Company ("Ordinary Shares") as a result of the exercise of warrants and options. Application has been made for the 467,024 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 28 December 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 181,230,758 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine...
Read More

Result of GM

By | AIM Investors
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that all resolutions put to shareholders at the Company's General Meeting held earlier today were duly passed. Company Contacts Motif Bio plc Graham Lumsden, Chief Executive Officer info@motifbio.com Zeus Capital Limited (Nominated Advisor and Broker) Phil Walker / Giles Balleny Dominic Wilson +44 (0) 20 3829 5000 Northland Capital Partners Limited (Broker) Patrick Claridge / David Hignell John Howes / Rob Rees (Broking) +44 (0) 207 382 1100 Walbrook PR Ltd. (Public and Investor Relations) Paul McManus / Mike Wort Main: +44 (0)20 7933 8780 Paul: +44 (0)7980 541 893 Mike: +44 (0)7900 608 002 motifbio@walbrookpr.com MC Services AG (European IR) Raimund Gabriel +49 (0) 89 210 2280
Read More